Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that its Board of Directors increased the company's share repurchase authorization by $250 million.
During the first three quarters of 2010, the company repurchased approximately 15 million shares of common stock for $750 million, fully utilizing its previous authorization, which was granted in January, 2010. The company had approximately 170 million shares outstanding as of September 30, 2010.
Quest Diagnostics performs RNA testing on patient specimens to detect more cases of HCV